Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.
How this was made
The 30-second read
Why it matters
The update combines (1) measurable launch traction and insurance formulary coverage expansion, (2) a new clinical execution milestone with Phase 3 sites activated and trial open/enrolling, and (3) a balance-sheet runway statement into H2 2027, which together can shift near-term expectations for growth and de-risking.
Market read
Traders may reprice MIST ahead of the 8:30am ET investor call based on the combination of launch momentum, insurance coverage expansion, and the operational start of the AFib-RVR Phase 3 trial, supported by a stated cash runway.
What to watch
SG&A rose sharply in Q2 due to launch-related personnel and costs; investors may scrutinize whether prescription growth is cost-efficient and whether AFib-RVR enrollment timelines slip beyond the stated second-half 2026 plan.
Background
Milestone Pharmaceuticals is commercializing CARDAMYST (etripamil) for PSVT and advancing a Phase 3 program (ReVeRA-301) to expand into AFib-RVR.
Ticker impact
Milestone reports Q2 2026 cash of $170.6M, CARDAMYST prescription growth, and that Phase 3 ReVeRA-301 for AFib-RVR is now open/enrolling.
Moderately positive bias for the next session and into the investor call, with upside skew if investors view coverage gains and trial activation as de-risking the growth path.
The article contains multiple fresh, company-specific operational updates (coverage jump to ~50%, prescriber and script acceleration, Phase 3 sites activated/open) and a concrete balance-sheet runway figure, which can re-rate expectations for launch momentum and future indication expansion.
Market effects
Adds incremental evidence of commercial uptake and formulary penetration for an intranasal cardiovascular drug, potentially supporting sentiment toward small-cap cardiovascular biopharma launches.
Limited direct regional spillover; EMA and NMPA timelines may influence broader European/China cardiovascular regulatory sentiment.
EMA decision timing in H1 2027 and China review status keep the program on the global regulatory radar, but impact is primarily company-specific.
Counterpoint
Despite formulary coverage gains, product revenue remains small ($0.6M in Q2), so the market may discount launch metrics until they translate into sustained quarterly revenue growth.
Key entities
- companyMilestone Pharmaceuticals Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and corporate updates.
- productCARDAMYST (etripamil) nasal spray
Approved for acute symptomatic episodes of PSVT; launch traction and formulary coverage are highlighted.
- clinical_trialReVeRA-301 (Phase 3 AFib-RVR)
Registrational Phase 3 trial for self-administered etripamil in AFib-RVR, now open and enrolling.
- regulatorEuropean Medicines Agency (EMA)
Review of the PSVT marketing authorization application is expected in H1 2027.
- regulatorChina NMPA
PSVT NDA review is underway; partner Everest Medicines handles engagement.
